---
title: Antimicrobial Resistance in Cirrhotic Patients
nct_id: NCT04915573
overall_status: UNKNOWN
sponsor: Mansoura University
study_type: OBSERVATIONAL
primary_condition: Cirrhosis
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04915573.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04915573"
ct_last_update_post_date: 2021-06-10
last_seen_at: "2026-05-12T07:05:01.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Antimicrobial Resistance in Cirrhotic Patients

**Official Title:** Antimicrobial Resistance Among Sputum Pathogens in Post Hepatitis Cirrhotic Patients

**NCT ID:** [NCT04915573](https://clinicaltrials.gov/study/NCT04915573)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 100
- **Lead Sponsor:** Mansoura University
- **Collaborators:** Tanta University
- **Conditions:** Cirrhosis
- **Start Date:** 2021-06-07
- **Completion Date:** 2021-09
- **CT.gov Last Update:** 2021-06-10

## Brief Summary

Cirrhotic patients are more vulnerable to bacterial infection, and infection is one of the most common causes of acute liver disease decompensation.

## Detailed Description

Cirrhotic patients are more vulnerable to bacterial infection which is a common cause of acute liver disease decompensation. The aim of this study will characterize the antimicrobial resistance and distribution of bacteria isolated from chronic hepatic patients with pulmonary infections, as well as to evaluate the antimicrobial susceptibility of bacteria isolated from sputum.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Inclusion Criteria:

1\. Adults' older than 18 years with clinical evidence of liver disease

Exclusion Criteria:

1. Pregnancy
2. Intensive care unite stay of more than 24 hours
3. Malignancy
4. Organ transplantation
5. Acquired immune deficiency syndrome
```

## Arms

- **patients with Cirrhosis** — Patient with clinical evidence of liver disease, portal hypertension, ultrasound or computed tomography results, laboratory data will be used to confirm liver disease

## Interventions

- **Specimen** (DIAGNOSTIC_TEST) — Sputum will be collected in clean disposable containers

## Primary Outcomes

- **Isolate Identification** _(time frame: One day)_ — Distribution of bacterial isolates from sputum of cirrhotic patients expressed by frequency of each isolate
- **Antimicrobial resistance** _(time frame: One day)_ — Antimicrobial susceptibility testing to antibiotics determined by kirby-bauer disk diffusion

## Locations (1)

- Tanta University Hospitals, Tanta, Egypt — _RECRUITING_

## Recent Field Changes (last 30 days)

- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.tanta university hospitals|tanta||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04915573.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04915573*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*